Orlistat is a potent, specific and long-acting lipase inhibitor. It exerts its therapeutic activity in the lumen of the stomach and upper small intestine by forming a covalent bond with the active serine site of gastric and pancreatic lipases. The inactivated enzyme is thus rendered unable to hydrolyze dietary fats in the form of triglycerides into absorbable free fatty acids and monog lycerides. As undigested triglycerides cannot be absorbed, a caloric deficit arises which has a positive effect on weight control. Systemic absorption of ortistat is therefore not needed for activity. At the recommended therapeutic dose of 120 mg three times a day, orlistat inhibit dietary fat absorption by approximately 30%.
The recommended dose of Xenobese is one 120 mg cap to be taken immediately before, during, or up to one hour after each main meal. If a meal is missed or contains no fat the dose to Xenobese should be omitted. Doses of Xenekal® above 120 mg three times daily have not been shown to provide additional benefits. The effect of Xenekal® results in an increase in fecal fat 24-48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pretreatment levels within 48-72 hours. Safety & efficacy of Xenekal® were investigated in clinical studies lasting up to 4 years. The recommended dose of Xenekal® for adolescents is as same as adults.
Undesirable effects of Xenobese are largely gastrointestinal in nature. Common gastrointestinal side effects are oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort etc. Influenza, anxiety. headache, fatigue etc may rarely occur in some patients. Rare cases of hypersensit ivity have been reported. Main clinical symptoms are pruritus, exanthema, urticaria, angioedema and anaphylaxis.
Xenobese is contraindicated in patients with chronic malabsorption syndrome, in patients with cholestasis and in patients who are hypersensitive to orlistat or to any of the other ingredients of the capsules.
No clinical data are available on pregnancies exposed to Xenobese. As it is not known whether Xenobese is excreted in breast milk. Xenobese should not be used during breastfeeding.
No interactions with commonly prescribed medications such as alcohol, digoxin, nifedipine, oral contraceptives, phenytoin, pravastatin, warfarin, or metformin, glibenclamide, fibrates, furosemide, captopril, or atenolol have been observed in studies.
Store in a cool and dry place below 30°C.
Keep out of reach of children.
Xenobese capsules: Each box contains 21 capsules in blister